Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 52 of the 53 references it cites were found in a registry or an index.
Abstract
The major known genetic risk for Alzheimer's disease (AD), apolipoprotein E-4 (APOE-4), is associated with lowered parietal, temporal, and posterior cingulate cerebral glucose metabolism in patients with a clinical diagnosis of AD. To determine cognitive and metabolic decline patterns according to genetic risk, we investigated cerebral metabolic rates by using positron emission tomography in middle-aged and older nondemented persons with normal memory performance. A single copy of the APOE-4 allele was associated with lowered inferior parietal, lateral temporal, and posterior cingulate metabolism, which predicted cognitive decline after 2 years of longitudinal follow-up. For the 20 nondemented subjects followed longitudinally, memory performance scores did not decline significantly, but cortical metabolic rates did. In APOE-4 carriers, a 4% left posterior cingulate metabolic decline was observed, and inferior parietal and lateral temporal regions demonstrated the greatest magnitude (5%) of metabolic decline after 2 years. These results indicate that the combination of cerebral metabolic rates and genetic risk factors provides a means for preclinical AD detection that will assist in response monitoring during experimental treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, oxidative stress, mitochondrial dysfunction, and glucose hypometabolism have been well documented in MCI and AD brain [8,53,74,75,76].”
From Mitochondrial Oxidative and Nitrosative Stress and Alzheimer Disease (2020) · cites this paper as [74]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It has been suggested that this association may account for the earlier onset of symptoms in E4 carriers (21–23).”
From Prediction of cognitive decline in normal elderly subjects with 2-[ 18 F]fluoro-2-deoxy- d -glucose/positron-emission tomography (FDG/PET) (2001) · cites this paper as [23]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Young, cognitively normal apoE4 carriers have glucose hypometabolism in brain regions affected by AD [29–31]”
From Neuronal Apolipoprotein E4 Expression Results in Proteome-Wide Alterations and Compromises Bioenergetic Capacity by Disrupting Mitochondrial Function (2019) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This suggests the possibility that an apoE-related decrease in brain metabolism may contribute to development of AD (Reiman et al., 1996; Reiman et al., 2004, 2005; Small et al., 2000).”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Small et al., 2000
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, studies looking at both young and old non-demented carriers of the apoE4 isoform observed a similar regional pattern of hypometabolism prior to the onset of disease that correlates with the changes seen in the AD brain.”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Small et al., 2000
Experimental — accuracy not yet measured
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Co-Planar Stereotaxic Atlas of the Human Brain
Talairach, J., & Tournoux, P. (1988) · Medical Entomology and Zoology · Cited by 11,798
Statistical parametric maps in functional imaging: A general linear approach
Friston, K. J., Holmes, A. P., Worsley, K. J., Poline, J. ‐., Frith, C. D., & Frackowiak, R. S. J. (1994) · Human Brain Mapping · doi:10.1002/hbm.460020402 · Cited by 9,688
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Self-citationMild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
Talairach, J., Tournoux, P., & Rayport, M. (1988) · Thieme eBooks · Cited by 5,058
Spatial registration and normalization of images
Friston, K. J., Ashburner, J., Frith, C. D., Poline, J. ‐., Heather, J. D., & Frackowiak, R. S. J. (1995) · Human Brain Mapping · doi:10.1002/hbm.460030303 · Cited by 4,028
Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Self-citationPopulation-Based Norms for the Mini-Mental State Examination by Age and Educational Level
Crum, R. M. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03500180078038 · Cited by 2,929
Research works printed but not linked: 3
- Rogers, S. L. & Friedhoff, L. T. (1996) Dementia 7, 293-303.
- Huang, S. C., Phelps, M. E., Hoffman, E. J., Sideris, K., Selin, C. J. & Kuhl, D. E. (1980) Am. J. Physiol. 238, E69-82.
- Benton, A. L. (1974) The Revised Visual Retention Test (Psychological Corp., New York).
Cited by
Items 601–700 of 796
Glucose hypometabolism and hyperphosphorylated Tau synergistically drive neuronal necroptosis
Chen, X., Li, S., Neubauer, A., Li, X., Mao, W., Brendel, M., Liu, J., Zhang, M., Yang, C., 许瑞胜, et al. (2026) · Neuron · doi:10.1016/j.neuron.2026.03.035 · Cited by 5
DeMayo, M. M., Lv, J., Duffy, S. L., D’Souza, A., Mowszowski, L., Naismith, S. L., & Calamante, F. (2023) · Brain Connectivity · doi:10.1089/brain.2022.0050 · Cited by 5
“Change within these regions has previously been linked to participants with high genetic risk for Alzheimer’s disease conferred by APOE genotype (Chen et al, 2015; Small et al, 2000).”
The microRNA-mediated gene regulatory network in the hippocampus and hypothalamus of the aging mouse
Munkhzul, C., Yi, S. S., Kim, J., Lee, S., Kim, H.-T., Moon, J., & Lee, M. (2023) · PLoS ONE · doi:10.1371/journal.pone.0291943 · Cited by 4
Leite, J., Hespanhol, R., & Buchpiguel, C. A. (2014) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2014.09.005 · Cited by 4
Evaluation of visual hallucination based on pareidolia testing in patients with Alzheimer’s Disease
Gümüşyayla, Ş., Bektaş, H., Akdeniz, G., Vural, G., & Yön, M. İ. (2018) · Medical Journal of Islamic World Academy of Sciences · doi:10.5505/ias.2018.69926 · Cited by 4
“Patients with AD show specific areas of temporal and parietal hypoperfusion on functional brain imaging (17, 18) as well as parietal hypoperfusion on SPECT studies (19).”
BackgroundRecognition and treatment of Alzheimer's disease: A case-based review
Marseille, D. M., & Silverman, D. H. S. (2006) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/153331750602100212 · Cited by 4
Self-citationVisual Hallucinations in Alzheimer's Disease
Holroyd, S. (2004) · KARGER eBooks · doi:10.1159/000080002 · Cited by 4
Bladowska, J., Zak, T., Zimny, A., Zacharzewska-Gondek, A., Gondek, T. M., Szewczyk, P., Noga, L., Noczyńska, A., & Sąsiadek, M. J. (2013) · Brain and Development · doi:10.1016/j.braindev.2013.11.008 · Cited by 4
“of posterior cingulate gyrus and precuneus due to functional connectivity with thalamus is called a thalamocortical portion of Papez’ circuit and is involved in the learning and memory processes, which deteriorate in dementia syndromes [22,23].”
Beyond the Genotype: A Multi-Omic Analysis of APOEe4’s Role in Alzheimer’s DiseasePreprint
Markov, Y., Priyanka, A., Xu, L., Wang, W., Thrush, K., González, J. T., Borrus, D. S., Kasamoto, J., Sehgal, R., Zou, G., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.16.682426 · Cited by 4
Menni, C. P., Martín, M. A. C., & Beunza, J. (2009) · Cited by 18
Chen, Y. J., Herrold, A. A., Walter, A. E., Reilly, J. L., Seidenberg, P. H., Nauman, E. A., Talavage, T. M., Vandenbergh, D. J., Slobounov, S., & Breiter, H. C. (2021) · Journal of Neurotrauma · doi:10.1089/neu.2020.7016 · Cited by 3
Reactivation of atrophic neurons in Alzheimer's disease
Swaab, D. F. (2003) · Neurological Research · doi:10.1179/016164103101201959 · Cited by 4
Effect of plant extracts against Alzheimer’s disease
Obulesu, M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-95762-5.00001-1 · Cited by 3
New Developments in the Treatment of Alzheimer’s Disease
Rabins, P. V., Graff‐Radford, N. R., Small, G. W., & Yaari, R. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.8002ah1c · Cited by 3
Self-citationImaging studies and APOE genotype in persons at risk for Alzheimer’s disease
Scarmeas, N., & Stern, Y. (1996) · Current Psychiatry Reports · doi:10.1007/s11920-996-0057-4 · Cited by 3
Neuroimaging in Alzheimer Disease
Kantarci, K., & Jack, C. R. (2006) · Springer eBooks · doi:10.1007/0-387-31216-1_8 · Cited by 3
Clinical Evaluation of Dementia and When to Perform PET
Ercoli, L. M., & Small, G. W. (2009) · Springer eBooks · doi:10.1007/978-0-387-76420-7_1 · Cited by 3
Self-citationThe treacherous path of truth-telling with demented patients
Chodosh, J. (2000) · Western Journal of Medicine · doi:10.1136/ewjm.173.5.323 · Cited by 3
Brain pathology and neuronal losses in the living brain of Alzheimer's patients
Barrio, J. R., Kepe, V., Satyamurthy, N., Huang, S., & Small, G. W. (2006) · International Congress Series · doi:10.1016/j.ics.2005.11.102 · Cited by 3
Self-citationHerholz, K. (2008) · Springer eBooks · doi:10.1007/978-88-470-0840-3_33 · Cited by 3
“In middle-aged and elderly asymptomatic ApoE 4-positive individuals, temporoparietal and posterior cingulate rCMRglc values decline by about 2% per year [ 20 ].”
BackgroundReiman, E. M., Caselli, R. J., Chen, K., & Alexander, G. E. (2004) · Springer eBooks · doi:10.1007/978-3-642-59300-0_12 · Cited by 3
Nuklearmedizin und Demenz?Anwendung bei Morbus Alzheimer
Asenbaum, S. (2003) · Der Radiologe · doi:10.1007/s00117-003-0919-2 · Cited by 4
Chen, M., Kretzschmar, D., Verdile, G., & Lardelli, M. T. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415894-8.00025-7 · Cited by 3
Stout, J. A., Anderson, R. J., Mahzarnia, A., Han, Z. Y., Beck, K., Browndyke, J. N., Johnson, K. G., O’Brien, R., & Badea, A. (2025) · Brain Structure and Function · doi:10.1007/s00429-025-02905-9 · Cited by 2
“…et al. 2008; Mahley et al. 2009; Sacks et al. 2000), metabolic conditions (hyperlipidemia, diabetes, systemic inflammation) (Chen and Zhong 2013; Small et al. 2000; Cole et al. 2007; Peila et al. 2002), and alternative neurodegenerative and vascular pathologies such as cerebral amyloid…”
Impacts of aging on brain metabolism
Rodrigues, B. A., Santiago, T. C., & Silva, J. D. N. (2025) · Progress in brain research · doi:10.1016/bs.pbr.2025.05.009 · Cited by 3
Sex differences in brain glucose metabolism and Alzheimer's disease risk and progression
Ramezan, M., Demetriou, A., Burke, S. N., Nalvarte, I., & Shin, A. C. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71491 · Cited by 2
“Brain glucose hypometabolism is an invariant feature of AD, 8,58–64 which exists decades before cognitive decline 65–67 and brain atrophy.”
Zou, S., Liu, Y., Xu, B., Li, J., & He, Z. (2025) · Ageing and Neurodegenerative Diseases · doi:10.20517/and.2024.35 · Cited by 3
Imaging Genetics of Neuropsychiatric Disease
Chen, J. A., & Coppola, G. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-397025-1.00130-5 · Cited by 2
PET e SPECT cerebrais na avaliação dos estados demenciais
Buchpiguel, C. A. (2001) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462001000500011 · Cited by 2
“Por exemplo, quando se verifica um maior grau de déficit metabólico ou de fluxo regional, estima-se um declínio cognitivo mais rápido e severo.(9) Com SPECT existem igualmente vários estudos mostrando correlação com análise histológica.”
BackgroundFunctional Imaging Studies of Human Cognition Using Positron Emission Tomography
Misciagna, S. (2013) · InTech eBooks · doi:10.5772/57124 · Cited by 2
“…cingulate, parietal, prefrontal, entorhinal and temporal Positron Emission Tomography - Recent Developments in Instrumentation, Research and Clinical Oncological Practice92 regions have been found to predict future cognitive decline in older APOE ε4 carriers than non-carriers (Small et al., 2000).”
BackgroundPatterson, J. C., Minagar, A., Natarajan, N., & Takalkar, A. M. (2009) · Future Neurology · doi:10.2217/fnl.10.4 · Cited by 2
PET Imaging Agents for Alzheimer’s Disease
Choi, S., Plöessl, K., Zhu, L., & Kung, H. F. (2017) · Topics in medicinal chemistry · doi:10.1007/7355_2016_18 · Cited by 4
MobileAid: A Fast and Effective Cognitive Aid System on Mobile Devices
Liu, X., Liu, B., Liu, G., Chen, F., & Xing, T. (2020) · IEEE Access · doi:10.1109/access.2020.2998280 · Cited by 2
“In addition, patients with cognitive decline may be suffering from Alzheimer, change of behavior, and degeneration of brain function [2], [3].”
BackgroundChoi, Y., Song, J. E., Kim, E., Kim, C. H., Lee, J. E., & Song, H. (2023) · Yonsei Medical Journal · doi:10.3349/ymj.2022.0554 · Cited by 2
Neuroimaging Alzheimer's disease
Toga, A. W., Mega, M. S., & Thompson, P. M. (2004) · Cambridge University Press eBooks · doi:10.1017/cbo9780511526886.009 · Cited by 2
Self-citationRemodeling of arachidonate and other polyunsaturated fatty acids in Alzheimer’s disease
Fonteh, A. N., & Harrington, M. G. (2004) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-7848-7_9 · Cited by 2
Kulasingam, S., Samsa, G. P., & Matchar, D. B. (2006) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/153331750602100203 · Cited by 2
Perturbed Brain Energy Metabolism in Alzheimer’s Disease and Diabetes
Wu, L. (2017) · KU ScholarWorks (University of Kansas) · Cited by 3
Emerging Therapeutic Strategies for Treating Alzheimer’s Disease in Primary Care
(2003) · The Primary Care Companion to The Journal of Clinical Psychiatry · doi:10.4088/pcc.v05n0604 · Cited by 2
Pietrini, P., Furey, M. L., Guazzelli, M., & Alexander, G. E. (2001) · Elsevier eBooks · doi:10.1016/b978-012351830-9/50020-2 · Cited by 2
Zhang, H., Chiu, P. W., Ip, I. N., Liu, T., Wong, G. H. Y., Song, Y., Wong, S. W. H., Herrup, K., & Mak, H. K. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.15399 · Cited by 1
“…hypometabolism was seen in the same regions of the brain in at-risk ApoE4 carriers as in patients with probable AD using 18F-fluorodeoxyglucose (FDG) PET, that is, based on studies in young (Reiman et al., 2004), middle age (Reiman et al., 1996) and elderly (Small et al., 2000) at-risk subjects.”
BackgroundMahley, R. W. (2025) · Springer eBooks · doi:10.1007/978-3-031-52641-1_2-1 · Cited by 2
Cell-type-specific APOE4 cascade across the Alzheimer’s disease continuum
Shostak, D. M., Liang, Z., & Huang, Y. (2026) · Neuron · doi:10.1016/j.neuron.2026.04.024 · Cited by 1
Evidence of APOE4‐ related brain vulnerabilities in verbal memory systems in midlife women
Wugalter, K. A., Thurston, R. C., Wu, M., Aizenstein, H. J., Kamboh, M. I., Karikari, T. K., & Maki, P. M. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71635 · Cited by 1
“51,52 Therefore,whileourfindingsareconsistentwiththecom-mon phenomenon of functional brain differences in the absence of behavioral or structural differences among APOE4 carriers that have been reported in mixed-sex, middle-aged samples, 10–20 longitudinal research is needed to better understand…”
Neuroimaging and fatal familial insomnia
Perani, D., & Cortelli, P. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139088268.050 · Cited by 1
Elgazzar, A. H. (2014) · Springer eBooks · doi:10.1007/978-3-319-03458-4_12 · Cited by 1
Möglichkeiten moderner Bildgebungstechnologien im Rahmen der Frühdiagnostik von Alzheimererkrankung
Unschuld, P. G. (2015) · Therapeutische Umschau · doi:10.1024/0040-5930/a000674 · Cited by 1
Advances in Alzheimer’s Disease Management
Gauthier, S. G., & Rosa‐Neto, P. (2012) · doi:10.2217/9781780840840 · Cited by 1
Computer-Based Assessment of Alzheimer’s Disease Employing fMRI and/or EEG: A Comprehensive Review
Tripoliti, E. E., Zervakis, M. E., & Fotiadis, D. I. (2014) · Neuromethods · doi:10.1007/7657_2014_70 · Cited by 1
13 Functional Imaging with FDG-PET in Mild Cognitive Impairment
Herholz, K. (2009) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195328875.003.0013 · Cited by 1
Neuroimaging Advances in Alzheimer's Disease
Schonhaut, D. R., & Rabinovici, G. D. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800105-9.00017-2 · Cited by 4
Brain Perfusion SPECT in Alzheimer’s Disease
Nemoto, K. (2017) · Springer eBooks · doi:10.1007/978-4-431-55133-1_11 · Cited by 1
Yao, Z., Hu, B., Hu, T., An, J., Song, D., & Zhong, N. (2017) · IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · doi:10.1109/bibm.2017.8217750 · Cited by 1
“Small showed small but consistent reduction in cognitive performance of APOE4 carriers compared with APOE4 noncarriers across the AD and nondemented groups [38].”
ResultChen, X., Paranjpe, M. D., Wang, R., Feng, D. D., Zhou, Y., & Initiative, A. D. N. (2018) · IFAC-PapersOnLine · doi:10.1016/j.ifacol.2019.02.002 · Cited by 1
New Nonlinear Machine Learning Algorithms With Applications to Biomedical Data Science
Wang, X. (2019) · D-Scholarship@Pitt (University of Pittsburgh) · Cited by 1
Huellner, M. W., Pizzuto, D. A., Mächler, P. C., & Sekine, T. (2020) · Springer eBooks · doi:10.1007/978-3-030-48419-4_20 · Cited by 1
Elgazzar, A. H., & Sarikaya, İ. (2018) · Springer eBooks · doi:10.1007/978-3-319-76156-5_8 · Cited by 1
Pösel, C., Wagner, D. C., Scheibe, J., Kranz, A., Bothe, V., Lange, F., Schäbitz, W. R., Minnerup, J., & Boltze, J. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x16639008 · Cited by 1
Mózgowy metabolizm glukozy i wybranych jej transporterów w chorobach neurodegeneracyjnych.
Białoń, N., Trzęsicki, M., Górka, M., Suszyńśki, K., & Górka, D. (2022) · Postępy Biochemii · doi:10.18388/pb.2021_463 · Cited by 1
Contemporary Trends in MRI and PET Imaging for the Early Diagnosis of Alzheimer’s Disease
Chan, B. (2022) · International journal of high school research · doi:10.36838/v4i6.2 · Cited by 1
Applications of fMRI to Neurodegenerative Disease
Mahmoud, S. Y., Moon, D., Lee, J. K., & Jones, S. E. (2023) · Springer eBooks · doi:10.1007/978-3-031-10909-6_36 · Cited by 1
Neuroimaging Techniques: CT, MRI, SPECT, PET
Foster, N. L. (2003) · Humana Press eBooks · doi:10.1007/978-1-59259-661-4_9 · Cited by 1
Mild Cognitive Impairment Neuroimaging Markers for Early Diagnosis of Dementia
Huang, C. C. (2003) · Figshare · Cited by 1
Functional neuroimaging in Alzheimer's disease
Matsuda, H. (2006) · Radiation Medicine · doi:10.1007/s11604-006-2408-9 · Cited by 1
“well before even mild or questionable dementia is recognized clinically.(16,17) PET measures of glucose hypometabolism reflect decreased synaptic activity due either to loss or dysfunction of synapses,(18) and regional metabolic deficits observed on PET may reflect projections from dysfunctional neurons in other brain…”
BackgroundPositron Emission Tomography in Alzheimer‘s Disease: Early Prediction and Differentiation
Mistur, R. L., Mosconi, L., Santi, S. D., Li, Y., Tsui, W., & de Leon, M. J. (2008) · Future Neurology · doi:10.2217/14796708.4.1.23 · Cited by 1
Zechner, S. (2005) · edoc (University of Basel) · doi:10.5167/uzh-49457 · Cited by 3
A Computational Model of Arterial Structures: A Relationship to Alzheimer´s Disease
Kristinsdottir, S. (2009) · UC Research Repository (University of Canterbury) · doi:10.26021/2677 · Cited by 2
11 The Early Detection of Alzheimer's Disease with Positron Emission Tomography
Mistur, R. L., Mosconi, L., Switalski, R., Santi, S. D., Li, Y., Glodzik, L., Bryś, M., Tsui, W., Rusinek, H., & de Leon, M. J. (2009) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195328875.003.0011 · Cited by 1
"Espectroscopia de prótons na demência de Alzheimer e no comprometimento cognitivo"
de Souza, A. S. (2005) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2005.tde-12042006-090739 · Cited by 1
Metabolic Abnormalities in Alzheimer Disease
Gebhardt, F. M., & Dodd, P. R. (2008) · Springer eBooks · doi:10.1007/978-0-387-79112-8_22 · Cited by 2
Neuroimaging: Anything to do with neurotherapeutics?
Masdeu, J. C., & Bakshi, R. (2005) · Neurotherapeutics · doi:10.1007/bf03206664 · Cited by 1
Chapter 15. Psychiatric Disorders in People With Dementia
Steinberg, M., & Lyketsos, C. G. (2009) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781585628940.lg15 · Cited by 3
Dang, P., Yu, F., Guo, T., Yan, J., Zhang, C., Cao, S., & Hashemifar, S. S. (2026) · medRxiv · doi:10.64898/2026.01.06.26343479 · Cited by 2
Disruptive effects of Abeta oligomers to the radial -arm maze performance of rats
Morgan-Paisley, K. (2008)
Virta, J. J. (2012) · UTUPub (University of Turku) · Cited by 1
What Functional Brain Imaging Will Mean for Neurology
Frackowiak, R. S. J., & Mazziotta, F. J. C. (2005) · Elsevier eBooks · doi:10.1016/b978-012738903-5/50030-8
[18F]Fluorodeoxyglucose Positron Emission Tomography in Alzheimer Disease and Related Disorders
MIYAZAWA, N., & Shinohar, T. (2012) · InTech eBooks · doi:10.5772/30326
“year (Small et al., 2000).”
About Array Processing Methods for Image Segmentation
Marot, J., Fossati, C., & Caulier, Y. (2009) · InTech eBooks · doi:10.5772/7456
Strategies for using Molecular Neuroimaging in Dementia
Foster, N. L. (2008) · Handbook of clinical neurology · doi:10.1016/s0072-9752(07)01207-9 · Cited by 1
“Preliminary studies suggest that FDG-PET or amyloid imaging might be able to identify impending dementia in those at genetic risk and accurately predict dementia in those with memory impairment (Reiman et al., 1996; Small et al., 2000; Chetelat et al., 2003; Drzezga et al., 2003).”
BackgroundImaging of the Geriatric Brain
Apostolova, L. G., Fleisher, A., Drzezga, A. E., Nair, A. K., & Sabbagh, M. N. (2014) · Wiley eBooks · doi:10.1002/9781118730676.ch7
Physiological Neuroimaging in Ageing and Dementia: Metabolic and Molecular Scanning
Donix, M., Bookheimer, S. Y., & Small, G. W. (2010) · Wiley eBooks · doi:10.1002/9780470669600.ch45
Self-citationBokde, A. L. W., Lopez‐Bayo, P., Meindl, T., Pechler, S., Born, C., Faltraco, F., Teipel, S. J., Moeller, H. –., & Hampel, H. J. (2006) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2006.05.233
Function and brain structure in aging with and without cognitive impairment
Solé‐Padullés, C. (2007) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona)
Functional MRI Studies in Ageing and Early Alzheimer's Disease
Vitolo, O. V., & Sperling, R. A. (2010) · Wiley eBooks · doi:10.1002/9780470669600.ch70
Memory, genes, and brain imaging : relating the APOE gene to brain function and structure
Lind, J. (2007) · Figshare
Molecular Neuroimaging of the Dementias
Dickerson, B. C. (2011) · Wiley eBooks · doi:10.1002/9781444344110.ch19
Epigenetic dysregulation and the pathophysiology of Alzheimer’s disease
Mastroeni, D. (2013) · Research Publications (Maastricht University) · doi:10.26481/dis.20130503dm
Baron, J., Chételat, G., Desgranges, B., & Eustache, F. (2004) · Springer eBooks · doi:10.1007/978-3-642-59300-0_11
“This region of the TPACx is part of the typical hypometabolic profile of mild AD (Baron 1998), and hypometabolism in this area relative to healthy controls has been documented in non-demented subjects at risk of developing AD, such as ApoE4 carriers (Small et al. 2000; Reiman et al. 1996) and asymptomatic carriers of…”
BackgroundApplications of fMRI to Neurodegenerative Disease
Mahmoud, S. Y., Jones, S. E., & Phillips, M. D. (2011) · Springer eBooks · doi:10.1007/978-1-4419-0345-7_32
The Biology of Aging and Related Nuclear Medicine Studies
Pierson, R. N., & Shreeve, W. W. (2003) · Springer eBooks · doi:10.1007/978-3-642-55539-8_13
The role of the medial temporal lobe in discriminating complex object and scene stimuli
Shine, J. P. (2013) · ORCA Online Research @Cardiff (Cardiff University)
Селезнева, Н. Д., If, R., Si, G., Fedorova, Y. B., Гантман, М. В., Коровайцева, Г. И., Станиславовна, К. С., & Rogaev, E. I. (2013) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-013-9872-3
“A series of studies directed to seeking genetic markers for the probable development of disease in first-degree relatives of AD patients and identifying the age patterns of the risk of developing the disease led to investigations of possible neuropsychological markers for AD in patients’ relatives [7, 12, 13].”
BackgroundNeuroimaging Studies in Alzheimer's Disease: A Review
Cuellar, H., Gómez‐Ramos, P., Riascos, R., & Alba, L. D. (2009) · The Neuroradiology Journal · doi:10.1177/197140090902200503
O3‐03–07: Reduced functional connectivity in middle‐aged APOE‐4 carriers
Wu, Z., Xie, C., Li, W., Antuono, P., Jones, J. L., & Li, S. (2008) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2008.05.429
Hemodynamic correlates of vascular risk factors in patients with Alzheimer's disease
Yamazaki, T. (2008) · Nosotchu · doi:10.3995/jstroke.30.660
Neuroimaging Changes in Preclinical Alzheimer's Disease
Horne, N. R., & Bondi, M. W. (2003) · Perspectives on Neurophysiology and Neurogenic Speech and Language Disorders · doi:10.1044/nnsld13.4.12
SPECIFIC AMYLOID-BETA OLIGOMERS IN HUMAN CEREBROSPINAL FLUID
Handoko, M. (2012) · University of Minnesota Digital Conservancy (University of Minnesota)
Metadata
- Authors
- Small, G. W., Ercoli, L. M., Silverman, D. H. S., Huang, S.-C., Komo, S., Bookheimer, S. Y., Lavretsky, H., Miller, K., Siddarth, P., Rasgon, N. L., Mazziotta, J. C., Saxena, S., Wu, H. M., Mega, M. S., Cummings, J. L., Saunders, A. M., Pericak-Vance, M. A., Roses, A. D., Barrio, J. R., & Phelps, M. E.
- Affiliations
- University of California, Los Angeles (US)
- Center on Aging and Department of Psychiatry and Biobehavioral Sciences, Neuropsychiatric Institute, 760 Westwood Plaza, Los Angeles, CA 90024; Departments of Molecular and Medical Pharmacology and Neurology, and Brain Mapping Center, University of California, Los Angeles, CA 90095; Department of Medicine, Duke University Medical Center, Durham, NC 27710; and Glaxo Wellcome Research and Development, Research Triangle Park, NC 27709
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2000-05-16
- Volume
- 97
- Issue
- 11
- Pages
- 6037-6042
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC18554
- OpenAlex
- W2164303459
- Cited by
- 790
- References
- 53
- Citations by year
- 2026: 13 · 2025: 8 · 2024: 12 · 2023: 17 · 2022: 20 · 2021: 17 · 2020: 24 · 2019: 20 · 2018: 17 · 2017: 22 · 2016: 17 · 2015: 14 · 2014: 27 · 2013: 34 · 2012: 30
- FWCI
- 29.72
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Energy
- Alzheimer's Association
- Ahmanson Foundation
- National Institutes of Health (AG10123, MH52453, NS26630)
- U.S. Public Health Service
- National Institute on Aging (AG-13308, P50AG016570, P50AG005128, R01AG013308, P60AG011268, P30AG010123, U24AG021886)
- National Institute of Mental Health (MH52453, R01MH052453)
- National Institute of Neurological Disorders and Stroke (P01NS026630, R01NS031153)
- National Center for Research Resources (M01RR000865)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- Alzheimer's disease, APOE ε4, genetic risk, brain glucose metabolism, cognitive decline, posterior cingulate cortex, inferior parietal cortex, lateral temporal cortex, preclinical Alzheimer's disease, memory performance, non-demented elderly, longitudinal follow-up
- MeSH terms
- Aged, Aged, 80 and over, Alleles, Alzheimer Disease, Apolipoproteins E, Brain, Cognition Disorders, Female, Follow-Up Studies, Genotype, Humans, Male, Memory Disorders, Middle Aged, Psychological Tests, Risk Factors, Tomography, Emission-Computed, Genetic Predisposition to Disease, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.